KIN
Kindred Biosciences, Inc. [KIN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
KIN Stock Summary
In the News
KIN Financial details
Company Rating
Neutral
Market Cap
0
Income
-43.62M
Revenue
7.93M
Book val./share
1.76
Cash/share
1.64
Dividend
-
Dividend %
-
Employees
63
Optionable
No
Shortable
Yes
Earnings
05 Aug 2021
P/E
-15.38
Forward P/E
-
PEG
4.61
P/S
-
P/B
5.39
P/C
5.64
P/FCF
-
Quick Ratio
8.56
Current Ratio
9.08
Debt / Equity
0.29
LT Debt / Equity
0.22
-
-
EPS (TTM)
-1.06
EPS next Y
-
EPS next Q
-
EPS this Y
-62.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
47.68%
EPS Q/Q
-12.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.06%
Inst Trans
0%
ROA
-25%
ROE
-32%
ROC
-0.22%
Gross Margin
89%
Oper. Margin
-47%
Profit Margin
-56%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.24-9.26
52W High
+2.78%
52W Low
+2.78%
RSI
-
Rel Volume
0.12
Avg Volume
1.51M
Volume
178.5K
Perf Week
0%
Perf Month
0%
Perf Quarter
0%
Perf Half Y
0%
-
-
-
-
Beta
1.31522
-
-
Volatility
0%, 0%
Prev Close
0%
Price
9.25
Change
0.11%
KIN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
| Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.06 | 0.11 | 1.07 | |
| Net income per share | -1.13 | -1.23 | -1.6 | -1.59 | -0.6 | |
| Operating cash flow per share | -0.95 | -0.87 | -1.45 | -1.46 | -0.25 | |
| Free cash flow per share | -0.99 | -1.11 | -1.9 | -1.68 | -0.34 | |
| Cash per share | 2.86 | 3.23 | 2.38 | 1.86 | 1.49 | |
| Book value per share | 2.9 | 3.38 | 2.94 | 2.12 | 1.72 | |
| Tangible book value per share | 2.9 | 3.38 | 2.94 | 2.12 | 1.72 | |
| Share holders equity per share | 2.9 | 3.38 | 2.94 | 2.12 | 1.72 | |
| Interest debt per share | 0 | 0 | 0 | 0.52 | 0.57 | |
| Market cap | 84.46M | 237.04M | 339.46M | 327.81M | 169.34M | |
| Enterprise value | 77.77M | 202.23M | 283.16M | 331.73M | 178.15M | |
| P/E ratio | -3.75 | -7.68 | -6.83 | -5.34 | -7.17 | |
| Price to sales ratio | 0 | 0 | 172.67 | 77.02 | 4.02 | |
| POCF ratio | -4.5 | -10.83 | -7.54 | -5.82 | -17.18 | |
| PFCF ratio | -4.28 | -8.53 | -5.76 | -5.06 | -12.55 | |
| P/B Ratio | 1.46 | 2.8 | 3.72 | 4 | 2.51 | |
| PTB ratio | 1.46 | 2.8 | 3.72 | 4 | 2.51 | |
| EV to sales | 0 | 0 | 144.03 | 77.95 | 4.23 | |
| Enterprise value over EBITDA | -3.48 | -6.65 | -5.79 | -5.64 | -11.65 | |
| EV to operating cash flow | -4.14 | -9.24 | -6.29 | -5.89 | -18.07 | |
| EV to free cash flow | -3.94 | -7.28 | -4.8 | -5.12 | -13.2 | |
| Earnings yield | -0.27 | -0.13 | -0.15 | -0.19 | -0.14 | |
| Free cash flow yield | -0.23 | -0.12 | -0.17 | -0.2 | -0.08 | |
| Debt to equity | 0 | 0 | 0 | 0.24 | 0.3 | |
| Debt to assets | 0 | 0 | 0 | 0.17 | 0.21 | |
| Net debt to EBITDA | 0.3 | 1.15 | 1.15 | -0.07 | -0.58 | |
| Current ratio | 15.01 | 13.58 | 5.27 | 7.76 | 9.08 | |
| Interest coverage | 0 | 0 | 0 | 0 | -10.92 | |
| Income quality | 0.83 | 0.71 | 0.91 | 0.92 | 0.45 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 11.23 | 8.91 | 0.52 | |
| Research and developement to revenue | 0 | 0 | 13.43 | 6.65 | 0.74 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.05 | 0.27 | 0.31 | 0.15 | 0.37 | |
| Capex to revenue | 0 | 0 | -7.08 | -1.98 | -0.09 | |
| Capex to depreciation | -6.14 | -12.46 | -17.29 | -3.32 | -0.78 | |
| Stock based compensation to revenue | 0 | 0 | 3.19 | 1.73 | 0.18 | |
| Graham number | 8.6 | 9.67 | 10.3 | 8.7 | 4.82 | |
| ROIC | -0.39 | -0.36 | -0.54 | -0.6 | -0.25 | |
| Return on tangible assets | -0.37 | -0.34 | -0.47 | -0.54 | -0.25 | |
| Graham Net | 2.66 | 2.99 | 1.97 | 1.1 | 0.78 | |
| Working capital | 54.17M | 75.79M | 64.89M | 69.12M | 55.73M | |
| Tangible asset value | 57.68M | 84.68M | 91.21M | 81.92M | 67.48M | |
| Net current asset value | 54.14M | 75.68M | 64.79M | 47.24M | 34.29M | |
| Invested capital | 0 | 0 | 0 | 0.24 | 0.3 | |
| Average receivables | 0 | 0 | 451.5K | 913K | 773.5K | |
| Average payables | 563.5K | 924.5K | 2.51M | 2.42M | 700.5K | |
| Average inventory | 0 | 0 | 1.79M | 3.89M | 2.21M | |
| Days sales outstanding | 0 | 0 | 167.65 | 79.16 | 5.4 | |
| Days payables outstanding | 0 | 0 | 4.03K | 780.99 | 11.44 | |
| Days of inventory on hand | 0 | 0 | 4.02K | 2.62K | 16.33 | |
| Receivables turnover | 0 | 0 | 2.18 | 4.61 | 67.57 | |
| Payables turnover | 0 | 0 | 0.09 | 0.47 | 31.9 | |
| Inventory turnover | 0 | 0 | 0.09 | 0.14 | 22.35 | |
| ROE | -0.39 | -0.36 | -0.54 | -0.75 | -0.35 | |
| Capex per share | -0.05 | -0.24 | -0.45 | -0.22 | -0.09 |
Quarterly Fundamentals Overview
Last date of statement is 2021-06-30 for Q2
| Metric | History | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.01 | 0.03 | 0.02 | 0.06 | 0.08 | |
| Net income per share | 0.61 | -0.32 | -0.29 | -0.24 | -0.21 | |
| Operating cash flow per share | 0.62 | -0.27 | -0.17 | -0.23 | -0.06 | |
| Free cash flow per share | 0.58 | -0.27 | -0.18 | -0.24 | -0.06 | |
| Cash per share | 1.71 | 1.59 | 1.48 | 1.54 | 1.64 | |
| Book value per share | 2.21 | 1.95 | 1.72 | 2.04 | 1.76 | |
| Tangible book value per share | 2.21 | 1.95 | 1.72 | 2.04 | 1.76 | |
| Share holders equity per share | 2.21 | 1.95 | 1.72 | 2.04 | 1.76 | |
| Interest debt per share | 0.51 | 0.53 | 0.53 | 0.5 | 0.53 | |
| Market cap | 176.19M | 168.65M | 169.43M | 204.21M | 415.19M | |
| Enterprise value | 169.38M | 172.37M | 178.25M | 211.89M | 391.7M | |
| P/E ratio | 1.83 | -3.31 | -3.7 | -5.24 | -10.69 | |
| Price to sales ratio | 4.45 | 161.7 | 178.16 | 85.27 | 117.38 | |
| POCF ratio | 7.27 | -16.18 | -25.83 | -21.71 | -156.97 | |
| PFCF ratio | 7.74 | -15.97 | -23.67 | -21.13 | -153.21 | |
| P/B Ratio | 2.03 | 2.2 | 2.51 | 2.44 | 5.2 | |
| PTB ratio | 2.03 | 2.2 | 2.51 | 2.44 | 5.2 | |
| EV to sales | 4.28 | 165.26 | 187.44 | 88.47 | 110.74 | |
| Enterprise value over EBITDA | 6.71 | -16.55 | -19.46 | -24.82 | -53.44 | |
| EV to operating cash flow | 6.99 | -16.54 | -27.17 | -22.53 | -148.09 | |
| EV to free cash flow | 7.44 | -16.32 | -24.9 | -21.92 | -144.54 | |
| Earnings yield | 0.14 | -0.08 | -0.07 | -0.05 | -0.02 | |
| Free cash flow yield | 0.13 | -0.06 | -0.04 | -0.05 | -0.01 | |
| Debt to equity | 0.23 | 0.27 | 0.3 | 0.25 | 0.29 | |
| Debt to assets | 0.17 | 0.19 | 0.21 | 0.19 | 0.21 | |
| Net debt to EBITDA | -0.27 | -0.36 | -0.96 | -0.9 | 3.2 | |
| Current ratio | 10.47 | 12.71 | 9.08 | 12.07 | 7.02 | |
| Interest coverage | 0 | -20.99 | -19.33 | 0 | -14.63 | |
| Income quality | 1.01 | 0.86 | 0.6 | 0.97 | 0.29 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.13 | 4.5 | 3.47 | 1.96 | 1.66 | |
| Research and developement to revenue | 0.19 | 7.08 | 8.02 | 2.63 | 1.58 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.06 | 0.01 | 0.09 | 0.03 | 0.02 | |
| Capex to revenue | -0.04 | -0.13 | -0.63 | -0.11 | -0.02 | |
| Capex to depreciation | -1.23 | -0.11 | -0.5 | -0.22 | -0.05 | |
| Stock based compensation to revenue | 0.05 | 2.01 | 1.58 | 1.04 | 0.43 | |
| Graham number | 5.52 | 3.77 | 3.35 | 3.3 | 2.92 | |
| ROIC | 0.22 | -0.13 | -0.12 | -0.09 | -0.09 | |
| Return on tangible assets | 0.21 | -0.12 | -0.12 | -0.09 | -0.09 | |
| Graham Net | 0.98 | 0.89 | 0.78 | 1.13 | 1.02 | |
| Working capital | 65.82M | 62.43M | 55.73M | 72.54M | 67.82M | |
| Tangible asset value | 86.82M | 76.54M | 67.48M | 83.79M | 79.77M | |
| Net current asset value | 43.65M | 39.75M | 34.29M | 52.9M | 49.98M | |
| Invested capital | 0.23 | 0.27 | 0.3 | 0.25 | 0.29 | |
| Average receivables | 253.5K | 501K | 681.5K | 6.67M | 7.14M | |
| Average payables | 1.74M | 493K | 246K | 249K | 639.5K | |
| Average inventory | 606.5K | 387.5K | 296.5K | 103.5K | 0 | |
| Days sales outstanding | 0.6 | 63.77 | 59.05 | 477.81 | 39.57 | |
| Days payables outstanding | 158.43 | 102.39 | 34.25 | 53.85 | 130.42 | |
| Days of inventory on hand | 96.45 | 113.9 | 48.9 | 0 | 0 | |
| Receivables turnover | 150.44 | 1.41 | 1.52 | 0.19 | 2.27 | |
| Payables turnover | 0.57 | 0.88 | 2.63 | 1.67 | 0.69 | |
| Inventory turnover | 0.93 | 0.79 | 1.84 | 0 | 0 | |
| ROE | 0.28 | -0.17 | -0.17 | -0.12 | -0.12 | |
| Capex per share | -0.04 | 0 | -0.02 | -0.01 | 0 |
KIN Frequently Asked Questions
What is Kindred Biosciences, Inc. stock symbol ?
Kindred Biosciences, Inc. is a US stock , located in Burlingame of California and trading under the symbol KIN
What is Kindred Biosciences, Inc. stock quote today ?
Kindred Biosciences, Inc. stock price is $9.25 today.
Is Kindred Biosciences, Inc. stock public?
Yes, Kindred Biosciences, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.51M
- Employee 63
- CEO Dr. Richard Chin
- Headquarters Burlingame,CALIFORNIA,US
- IPO Date 2013-12-12
-
Website
http://www.kindredbio.com 
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
